日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial

PIK3CA突变结肠癌患者的阿司匹林辅助治疗:SAKK 41/13前瞻性随机安慰剂对照双盲试验

Güller, Ulrich; Hayoz, Stefanie; Horber, Daniel; Jochum, Wolfram; De Dosso, Sara; Koeberle, Dieter; Schacher, Sabina; Inauen, Roman; Stahl, Michael; Delaunoit, Thierry; Ettrich, Thomas; Bodoky, György; Michel, Pierre; Koessler, Thibaud; Rothgiesser, Karin; Calmonte, Sandra; Joerger, Markus

SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients

SAKK 21/12:CR1447经皮给药治疗乳腺癌患者的II期临床试验

Vetter, Marcus; Rothgiesser, Karin M; Li, Qiyu; Hawle, Hanne; Schönfeld, Wolfgang; Ribi, Karin; Riniker, Salome; von Moos, Roger; Trojan, Andreas; Kralidis, Elena; Fehr, Mathias; Müller, Andreas; Thürlimann, Beat

Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99

血浆 HER2ECD 检测在 HER2 阳性乳腺癌患者预后和疗效预测方面具有应用前景:一项随机研究的结果 - SAKK 22/99

Eppenberger-Castori, Serenella; Klingbiel, Dirk; Ruhstaller, Thomas; Dietrich, Daniel; Rufle, Daniel Alexander; Rothgiesser, Karin; Pagani, Olivia; Thürlimann, Beat

Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients

雄激素受体调节剂 CR1447 在乳腺癌患者中的 I 期试验

Zweifel, Martin; Thürlimann, Beat; Riniker, Salome; Weder, Patrik; von Moos, Roger; Pagani, Olivia; Bigler, Martin; Rothgiesser, Karin M; Pilop, Christiane; Hawle, Hanne; Brauchli, Peter; Tapia, Coya; Schoenfeld, Wolfgang; Sessa, Cristiana

Functional relevance of novel p300-mediated lysine 314 and 315 acetylation of RelA/p65

新型 p300 介导的 RelA/p65 赖氨酸 314 和 315 乙酰化的功能相关性

Christine Buerki, Karin M Rothgiesser, Taras Valovka, Heather R Owen, Hubert Rehrauer, Monika Fey, William S Lane, Michael O Hottiger